{"count": 11, "results": [{"_id": "35273491", "pmid": 35273491, "pmcid": "PMC8902410", "title": "Effects of Irbesartan and Amlodipine Besylate Tablets on the Intestinal Microflora of Rats With Hypertensive Renal Damage", "journal": "Front Pharmacol", "authors": ["Yu J", "Ma Y", "He X", "Long XN", "Xu J", "Wang L", "Feng ZP", "Peng HY"], "date": "2022-02-22T00:00:00Z", "doi": "10.3389/fphar.2021.778072", "meta_date_publication": "2021", "meta_volume": "12", "meta_issue": "", "meta_pages": "778072", "score": 50293.035, "text_hl": "Effects of @CHEMICAL_Irbesartan @CHEMICAL_MESH:D000077405 @@@Irbesartan@@@ and @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@Amlodipine Besylate@@@ Tablets on the Intestinal Microflora of @SPECIES_10116 @@@Rats@@@ With @<m>DISEASE_Hypertension_Renal</m> @DISEASE_MESH:D006977 @@@Hypertensive Renal Damage@@@", "citations": {"NLM": "Yu J, Ma Y, He X, Long XN, Xu J, Wang L, Feng ZP, Peng HY. Effects of Irbesartan and Amlodipine Besylate Tablets on the Intestinal Microflora of Rats With Hypertensive Renal Damage Front Pharmacol. 2021;12():778072. PMID: 35273491", "BibTeX": "@article{35273491, title={Effects of Irbesartan and Amlodipine Besylate Tablets on the Intestinal Microflora of Rats With Hypertensive Renal Damage}, author={Yu J and Ma Y and He X and Long XN and Xu J and Wang L and Feng ZP and Peng HY}, journal={Front Pharmacol}, volume={12}, pages={778072}}"}}, {"_id": "37154141", "pmid": 37154141, "title": "Folic acid enhances the cardiovascular protective effect of amlodipine in renal hypertensive rats with elevated homocysteine.", "journal": "Clin Exp Hypertens", "authors": ["Li L", "Tong X", "Ma Z", "Lv L", "Liu H", "Chen GL"], "date": "2023-12-31T00:00:00Z", "doi": "10.1080/10641963.2023.2205058", "meta_date_publication": "2023 Dec 31", "meta_volume": "45", "meta_issue": "1", "meta_pages": "2205058", "score": 50269.25, "text_hl": "@CHEMICAL_Folic_Acid @CHEMICAL_MESH:D005492 @@@Folic acid@@@ enhances the cardiovascular protective effect of @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ in @<m>DISEASE_Hypertension_Renal</m> @DISEASE_MESH:D006977 @@@renal hypertensive@@@ @SPECIES_10116 @@@rats@@@ with elevated @CHEMICAL_Homocysteine @CHEMICAL_MESH:D006710 @@@homocysteine@@@.", "citations": {"NLM": "Li L, Tong X, Ma Z, Lv L, Liu H, Chen GL. Folic acid enhances the cardiovascular protective effect of amlodipine in renal hypertensive rats with elevated homocysteine. Clin Exp Hypertens. 2023 Dec 31;45(1):2205058. PMID: 37154141", "BibTeX": "@article{37154141, title={Folic acid enhances the cardiovascular protective effect of amlodipine in renal hypertensive rats with elevated homocysteine.}, author={Li L and Tong X and Ma Z and Lv L and Liu H and Chen GL}, journal={Clin Exp Hypertens}, volume={45}, number={1}, pages={2205058}}"}}, {"_id": "1829060", "pmid": 1829060, "title": "[Antihypertensive effects of amlodipine, a new calcium antagonist].", "journal": "Nihon Yakurigaku Zasshi", "authors": ["Yamanaka K", "Suzuki M", "Munehasu S", "Ishiko J"], "date": "1991-02-01T00:00:00Z", "doi": "10.1254/fpj.97.2_115", "meta_date_publication": "1991 Feb", "meta_volume": "97", "meta_issue": "2", "meta_pages": "115-26", "score": 50070.43, "text_hl": "The ED30 values were 2.4 and 2.2 mg/kg and similar to the respective values of @CHEMICAL_Nifedipine @CHEMICAL_MESH:D009543 @@@nifedipine@@@ (ED 30:2.4,2.1 mg/kg). In @<m>DISEASE_Hypertension_Renal</m> @DISEASE_MESH:D006977 @@@renal hypertensive@@@ @SPECIES_9615 @@@dogs@@@ (RHD), the effect of @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@AML@@@ (0.1,0.3,1.0 mg/kg) was maximum at 4-6 hr and long-lasting, producing similar reductions of both systolic and diastolic @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@BP@@@ (ED30: 0.3-0.4 mg/kg respectively). ", "citations": {"NLM": "Yamanaka K, Suzuki M, Munehasu S, Ishiko J. [Antihypertensive effects of amlodipine, a new calcium antagonist]. Nihon Yakurigaku Zasshi. 1991 Feb;97(2):115-26. PMID: 1829060", "BibTeX": "@article{1829060, title={[Antihypertensive effects of amlodipine, a new calcium antagonist].}, author={Yamanaka K and Suzuki M and Munehasu S and Ishiko J}, journal={Nihon Yakurigaku Zasshi}, volume={97}, number={2}, pages={115-26}}"}}, {"_id": "11386927", "pmid": 11386927, "title": "Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.", "journal": "JAMA", "authors": ["Agodoa LY", "Appel L", "Bakris GL", "Beck G", "Bourgoignie J", "Briggs JP", "Charleston J", "Cheek D", "Cleveland W", "Douglas JG", "Douglas M", "Dowie D", "Faulkner M", "Gabriel A", "Gassman J", "Greene T", "Hall Y", "Hebert L", "Hiremath L", "Jamerson K", "Johnson CJ", "Kopple J", "Kusek J", "Lash J", "Lea J", "Lewis JB", "Lipkowitz M", "Massry S", "Middleton J", "Miller ER 3rd", "Norris K", "O'Connor D", "Ojo A", "Phillips RA", "Pogue V", "Rahman M", "Randall OS", "Rostand S", "Schulman G", "Smith W", "Thornley-Brown D", "Tisher CC", "Toto RD", "Wright JT Jr", "Xu S", "African American Study of Kidney Disease and Hypertension (AASK) Study Group"], "date": "2001-06-06T00:00:00Z", "doi": "10.1001/jama.285.21.2719", "meta_date_publication": "2001 Jun 6", "meta_volume": "285", "meta_issue": "21", "meta_pages": "2719-28", "score": 50068.605, "text_hl": "OBJECTIVE: To compare the effects of an angiotensin-converting enzyme (ACE) inhibitor (@CHEMICAL_Ramipril @CHEMICAL_MESH:D017257 @@@ramipril@@@), a @CHEMICAL_1_4_dihydropyridine @CHEMICAL_MESH:C038806 @@@dihydropyridine@@@ calcium channel blocker (@<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@), and a beta-blocker (@CHEMICAL_Metoprolol @CHEMICAL_MESH:D008790 @@@metoprolol@@@) on @<m>DISEASE_Hypertension_Renal</m> @DISEASE_MESH:D006977 @@@hypertensive renal disease@@@ progression. ", "citations": {"NLM": "Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S, African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001 Jun 6;285(21):2719-28. PMID: 11386927", "BibTeX": "@article{11386927, title={Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.}, author={Agodoa LY and Appel L and Bakris GL and Beck G and Bourgoignie J and Briggs JP and Charleston J and Cheek D and Cleveland W and Douglas JG and Douglas M and Dowie D and Faulkner M and Gabriel A and Gassman J and Greene T and Hall Y and Hebert L and Hiremath L and Jamerson K and Johnson CJ and Kopple J and Kusek J and Lash J and Lea J and Lewis JB and Lipkowitz M and Massry S and Middleton J and Miller ER 3rd and Norris K and O'Connor D and Ojo A and Phillips RA and Pogue V and Rahman M and Randall OS and Rostand S and Schulman G and Smith W and Thornley-Brown D and Tisher CC and Toto RD and Wright JT Jr and Xu S and African American Study of Kidney Disease and Hypertension (AASK) Study Group}, journal={JAMA}, volume={285}, number={21}, pages={2719-28}}"}}, {"_id": "19907160", "pmid": 19907160, "title": "CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.", "journal": "Am J Nephrol", "authors": ["Bhatnagar V", "Garcia EP", "O'Connor DT", "Brophy VH", "Alcaraz J", "Richard E", "Bakris GL", "Middleton JP", "Norris KC", "Wright J", "Hiremath L", "Contreras G", "Appel LJ", "Lipkowitz MS", "AASK Study Investigators"], "date": "2010-01-01T00:00:00Z", "doi": "10.1159/000258688", "meta_date_publication": "2010", "meta_volume": "31", "meta_issue": "2", "meta_pages": "95-103", "score": 50063.043, "text_hl": "@GENE_CYP3A4 @GENE_1576 @@@CYP3A4@@@ and @GENE_CYP3A5 @GENE_1577 @@@CYP3A5@@@ polymorphisms and blood pressure response to @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ among African-American @SPECIES_9606 @@@men@@@ and @SPECIES_9606 @@@women@@@ with early @<m>DISEASE_Hypertension_Renal</m> @DISEASE_MESH:D006977 @@@hypertensive renal disease@@@.", "citations": {"NLM": "Bhatnagar V, Garcia EP, O'Connor DT, Brophy VH, Alcaraz J, Richard E, Bakris GL, Middleton JP, Norris KC, Wright J, Hiremath L, Contreras G, Appel LJ, Lipkowitz MS, AASK Study Investigators. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol. 2010;31(2):95-103. PMID: 19907160", "BibTeX": "@article{19907160, title={CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.}, author={Bhatnagar V and Garcia EP and O'Connor DT and Brophy VH and Alcaraz J and Richard E and Bakris GL and Middleton JP and Norris KC and Wright J and Hiremath L and Contreras G and Appel LJ and Lipkowitz MS and AASK Study Investigators}, journal={Am J Nephrol}, volume={31}, number={2}, pages={95-103}}"}}, {"_id": "19947495", "pmid": 19947495, "title": "[Intermedin (IMD) gene expression in hypertrophic cardiac myocyte of renal vascular hypertension rats and the intervention of Valsartan, Amlodipine and Enalapril in the expression].", "journal": "Sheng Wu Yi Xue Gong Cheng Xue Za Zhi", "authors": ["Dong J", "Chen X", "So Y", "Xin H", "Jiang W", "Jiang L"], "date": "2009-10-01T00:00:00Z", "meta_date_publication": "2009 Oct", "meta_volume": "26", "meta_issue": "5", "meta_pages": "1082-7", "score": 50055.215, "text_hl": "[@GENE_ADM2 @GENE_399475 @@@Intermedin@@@ (@GENE_ADM2 @GENE_399475 @@@IMD@@@) gene expression in @DISEASE_Heart_Diseases @DISEASE_MESH:D006331 @@@hypertrophic cardiac myocyte@@@ of @<m>DISEASE_Hypertension_Renal</m> @DISEASE_MESH:D006977 @@@renal vascular hypertension@@@ @SPECIES_10116 @@@rats@@@ and the intervention of @CHEMICAL_Valsartan @CHEMICAL_MESH:D000068756 @@@Valsartan@@@, @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@Amlodipine@@@ and @CHEMICAL_Enalapril @CHEMICAL_MESH:D004656 @@@Enalapril@@@ in the expression].", "citations": {"NLM": "Dong J, Chen X, So Y, Xin H, Jiang W, Jiang L. [Intermedin (IMD) gene expression in hypertrophic cardiac myocyte of renal vascular hypertension rats and the intervention of Valsartan, Amlodipine and Enalapril in the expression]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2009 Oct;26(5):1082-7. PMID: 19947495", "BibTeX": "@article{19947495, title={[Intermedin (IMD) gene expression in hypertrophic cardiac myocyte of renal vascular hypertension rats and the intervention of Valsartan, Amlodipine and Enalapril in the expression].}, author={Dong J and Chen X and So Y and Xin H and Jiang W and Jiang L}, journal={Sheng Wu Yi Xue Gong Cheng Xue Za Zhi}, volume={26}, number={5}, pages={1082-7}}"}}, {"_id": "27841150", "pmid": 27841150, "title": "CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation : .", "journal": "Int J Clin Pharmacol Ther", "authors": ["Huang Y", "Wen G", "Lu Y", "Wen J", "Ji Y", "Xing X", "Li Y", "Wen J", "Yuan H"], "date": "2017-02-01T00:00:00Z", "doi": "10.5414/CP202559", "meta_date_publication": "2017 Feb", "meta_volume": "55", "meta_issue": "2", "meta_pages": "109-118", "score": 50052.523, "text_hl": "OBJECTIVE: Previous studies have determined that @GENE_CYP3A4 @GENE_1576 @@@CYP3A@@@ and @GENE_ABCB1 @GENE_5243 @@@multidrug resistance protein 1@@@ (@GENE_ABCB1 @GENE_5243 @@@MDR1@@@) polymorphisms can affect the pharmacokinetics and pharmacodynamics of @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ in both healthy subjects and those with early @<m>DISEASE_Hypertension_Renal</m> @DISEASE_MESH:D006977 @@@hypertensive renal disease@@@. ", "citations": {"NLM": "Huang Y, Wen G, Lu Y, Wen J, Ji Y, Xing X, Li Y, Wen J, Yuan H. CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation : . Int J Clin Pharmacol Ther. 2017 Feb;55(2):109-118. PMID: 27841150", "BibTeX": "@article{27841150, title={CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation : .}, author={Huang Y and Wen G and Lu Y and Wen J and Ji Y and Xing X and Li Y and Wen J and Yuan H}, journal={Int J Clin Pharmacol Ther}, volume={55}, number={2}, pages={109-118}}"}}, {"_id": "21784887", "pmid": 21784887, "title": "Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension.", "journal": "J Pharmacol Exp Ther", "authors": ["Zhao X", "Ho D", "Abarzúa P", "Dhar SK", "Wang X", "Jia Z", "Pannirselvam M", "Morgans DJ", "Malik FI", "Vatner SF"], "date": "2011-10-01T00:00:00Z", "doi": "10.1124/jpet.111.182402", "meta_date_publication": "2011 Oct", "meta_volume": "339", "meta_issue": "1", "meta_pages": "307-12", "score": 50052.324, "text_hl": "Patent Publication 2009-0275537 A1) in conscious @SPECIES_9615 @@@dogs@@@ with @<m>DISEASE_Hypertension_Renal</m> @DISEASE_MESH:D006977 @@@renal hypertension@@@ and compared its efficacy with that of a @CHEMICAL_Calcium @CHEMICAL_MESH:D002118 @@@calcium@@@ channel blocker, @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@. ", "citations": {"NLM": "Zhao X, Ho D, Abarzúa P, Dhar SK, Wang X, Jia Z, Pannirselvam M, Morgans DJ, Malik FI, Vatner SF. Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension. J Pharmacol Exp Ther. 2011 Oct;339(1):307-12. PMID: 21784887", "BibTeX": "@article{21784887, title={Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension.}, author={Zhao X and Ho D and Abarzúa P and Dhar SK and Wang X and Jia Z and Pannirselvam M and Morgans DJ and Malik FI and Vatner SF}, journal={J Pharmacol Exp Ther}, volume={339}, number={1}, pages={307-12}}"}}, {"_id": "12435255", "pmid": 12435255, "title": "Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.", "journal": "JAMA", "authors": ["Wright JT Jr", "Bakris G", "Greene T", "Agodoa LY", "Appel LJ", "Charleston J", "Cheek D", "Douglas-Baltimore JG", "Gassman J", "Glassock R", "Hebert L", "Jamerson K", "Lewis J", "Phillips RA", "Toto RD", "Middleton JP", "Rostand SG", "African American Study of Kidney Disease and Hypertension Study Group"], "date": "2002-11-20T00:00:00Z", "doi": "10.1001/jama.288.19.2421", "meta_date_publication": "2002 Nov 20", "meta_volume": "288", "meta_issue": "19", "meta_pages": "2421-31", "score": 50044.83, "text_hl": "There was no significant difference in the clinical composite outcome between the @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ and @CHEMICAL_Metoprolol @CHEMICAL_MESH:D008790 @@@metoprolol@@@ groups. ", "citations": {"NLM": "Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG, African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20;288(19):2421-31. PMID: 12435255", "BibTeX": "@article{12435255, title={Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.}, author={Wright JT Jr and Bakris G and Greene T and Agodoa LY and Appel LJ and Charleston J and Cheek D and Douglas-Baltimore JG and Gassman J and Glassock R and Hebert L and Jamerson K and Lewis J and Phillips RA and Toto RD and Middleton JP and Rostand SG and African American Study of Kidney Disease and Hypertension Study Group}, journal={JAMA}, volume={288}, number={19}, pages={2421-31}}"}}, {"_id": "15851648", "pmid": 15851648, "title": "The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.", "journal": "Arch Intern Med", "authors": ["Lea J", "Greene T", "Hebert L", "Lipkowitz M", "Massry S", "Middleton J", "Rostand SG", "Miller E", "Smith W", "Bakris GL"], "date": "2005-04-25T00:00:00Z", "doi": "10.1001/archinte.165.8.947", "meta_date_publication": "2005 Apr 25", "meta_volume": "165", "meta_issue": "8", "meta_pages": "947-53", "score": 50040.207, "text_hl": "A total of 1094 African Americans with @<m>DISEASE_Hypertension_Renal</m> @DISEASE_MESH:D006977 @@@hypertensive renal disease@@@ (GFR, 20-65 mL/min per 1.73 m(2)) were followed up for a median of 3.8 years. ", "citations": {"NLM": "Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005 Apr 25;165(8):947-53. PMID: 15851648", "BibTeX": "@article{15851648, title={The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.}, author={Lea J and Greene T and Hebert L and Lipkowitz M and Massry S and Middleton J and Rostand SG and Miller E and Smith W and Bakris GL}, journal={Arch Intern Med}, volume={165}, number={8}, pages={947-53}}"}}]}